PubMed
An exercise-inducible metabolite that increases endurance via the ERRγ pathway
Li et al., 2023
GLP-1 & MetabolicResearch OnlyC
SLU-PP-332
ERR Pan-Agonist
Exercise-mimetic metabolic research compound (non-peptide) explored for endurance pathways.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 56
- Activity
- 64
Overall check-ins
Trackers & reports
Overview
About SLU-PP-332
Exercise-mimetic metabolic research compound (non-peptide) explored for endurance pathways.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Research Only
- Also known as
- ERR Pan-Agonist
- Self-reports
- 27
Community
What 27 users report
27 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
141
Appetite
141
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
137
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
0.2–0.4 mg
26
0.4–0.6 mg
2
0.6–1 mg
1
1–2 mg
5
2–3 mg
1
5+ mg
106
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 84% said they felt similar to their last entry, 16% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 25 repeat reporters
Research
Cited research (3)
Source
PubMed
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon et al., 2024
PubMed
Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling
Okda et al., 2026
Tools
Explore more
Explore
More ways to learn about SLU-PP-332 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about SLU-PP-332?
This page summarizes 27 anonymized self-reports from PeptIQ users who track SLU-PP-332, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for SLU-PP-332?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for SLU-PP-332?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is SLU-PP-332 safe to use?
This wiki does not assess safety or recommend use. SLU-PP-332 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of SLU-PP-332?
This wiki summarizes observational community reports and linked citations for SLU-PP-332. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for SLU-PP-332 for study-level context — not medical advice.
What is the legal status of SLU-PP-332?
SLU-PP-332 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of SLU-PP-332?
Safety data quality for SLU-PP-332 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on SLU-PP-332?
This page links 3 indexed sources for SLU-PP-332. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.